MFA Wealth Advisors LLC Has $87,000 Stock Position in Novo Nordisk A/S (NYSE:NVO)

MFA Wealth Advisors LLC lifted its position in shares of Novo Nordisk A/S (NYSE:NVO) by 184.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 728 shares of the company’s stock after purchasing an additional 472 shares during the quarter. MFA Wealth Advisors LLC’s holdings in Novo Nordisk A/S were worth $87,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. 1620 Investment Advisors Inc. acquired a new stake in Novo Nordisk A/S during the second quarter worth $25,000. Strategic Investment Solutions Inc. IL acquired a new stake in shares of Novo Nordisk A/S during the 2nd quarter valued at about $25,000. Dixon Mitchell Investment Counsel Inc. acquired a new stake in shares of Novo Nordisk A/S during the 1st quarter valued at about $26,000. Orion Capital Management LLC acquired a new position in Novo Nordisk A/S in the first quarter worth about $26,000. Finally, Gilliland Jeter Wealth Management LLC raised its holdings in shares of Novo Nordisk A/S by 200.0% in the 2nd quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock worth $26,000 after buying an additional 120 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Price Performance

Novo Nordisk A/S stock opened at $115.70 on Thursday. The business’s fifty day moving average is $127.52 and its two-hundred day moving average is $131.50. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.75 and a current ratio of 0.94. The firm has a market cap of $519.21 billion, a P/E ratio of 39.62, a P/E/G ratio of 1.54 and a beta of 0.42. Novo Nordisk A/S has a 52 week low of $92.94 and a 52 week high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Wednesday, August 7th. The company reported $0.65 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.71 by ($0.06). Novo Nordisk A/S had a return on equity of 87.43% and a net margin of 34.86%. The company had revenue of $9.82 billion for the quarter, compared to analyst estimates of $9.91 billion. Equities research analysts forecast that Novo Nordisk A/S will post 3.01 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The business also recently declared a semi-annual dividend, which was paid on Monday, August 26th. Stockholders of record on Friday, August 16th were paid a dividend of $0.5126 per share. The ex-dividend date of this dividend was Friday, August 16th. This represents a dividend yield of 0.7%. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 24.66%.

Wall Street Analysts Forecast Growth

NVO has been the topic of a number of analyst reports. BMO Capital Markets lowered their price target on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a research report on Thursday, October 17th. StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, October 9th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research report on Thursday, October 10th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, Novo Nordisk A/S presently has an average rating of “Moderate Buy” and an average target price of $144.50.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.